Sign up
Pharma Capital

Medexus Pharmaceuticals will begin selling Treosulfan in Canada, and will soon look to the US

Medexus Pharmaceuticals Inc (CVE:MDP) (OTC:PDDPF) CEO Ken d’Entremont tells Proactive Investors that Health Canada has authorized the Montreal-based specialty pharma company to distribute Treosulfan through the special access program.

Treosulfana conditioning agent used before stem cell transplantation.

The company will look to bring Treosulfann to the US, according to d'Entremont.

 

View full MDP profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.